Sovran Advisors LLC Invests $3.21 Million in Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Sovran Advisors LLC bought a new position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 27,015 shares of the biotechnology company's stock, valued at approximately $3,210,000.

A number of other hedge funds have also recently bought and sold shares of SRPT. MassMutual Private Wealth & Trust FSB grew its holdings in Sarepta Therapeutics by 169.6% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company's stock worth $30,000 after acquiring an additional 156 shares during the period. Sunbelt Securities Inc. boosted its position in shares of Sarepta Therapeutics by 446.2% in the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 232 shares during the period. Huntington National Bank boosted its position in shares of Sarepta Therapeutics by 150.9% in the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 175 shares during the period. Newbridge Financial Services Group Inc. acquired a new position in shares of Sarepta Therapeutics in the 4th quarter valued at $36,000. Finally, UMB Bank n.a. boosted its position in shares of Sarepta Therapeutics by 105.9% in the 3rd quarter. UMB Bank n.a. now owns 383 shares of the biotechnology company's stock valued at $48,000 after purchasing an additional 197 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Sarepta Therapeutics Stock Performance

Shares of SRPT stock traded down $1.51 during trading on Friday, reaching $107.95. The company had a trading volume of 630,697 shares, compared to its average volume of 800,737. The firm's 50 day simple moving average is $119.42 and its two-hundred day simple moving average is $124.85. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. Sarepta Therapeutics, Inc. has a one year low of $102.15 and a one year high of $173.25. The company has a market capitalization of $10.31 billion, a PE ratio of 86.36 and a beta of 0.75.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on the company. Needham & Company LLC reiterated a "buy" rating and issued a $202.00 price target on shares of Sarepta Therapeutics in a research report on Monday, January 27th. Robert W. Baird decreased their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a research report on Monday, October 21st. They issued a "buy" rating and a $165.00 price target for the company. Royal Bank of Canada reiterated an "outperform" rating and issued a $182.00 price target on shares of Sarepta Therapeutics in a research report on Monday, October 21st. Finally, Deutsche Bank Aktiengesellschaft started coverage on Sarepta Therapeutics in a research report on Tuesday. They set a "hold" rating and a $136.00 price objective for the company. One analyst has rated the stock with a sell rating, three have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Sarepta Therapeutics has a consensus rating of "Moderate Buy" and an average price target of $176.77.

Insider Activity at Sarepta Therapeutics

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the transaction, the director now directly owns 5,880 shares of the company's stock, valued at $738,234. The trade was a 21.77 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction that occurred on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. This represents a 31.49 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.